Daily Low-Dose chemo tested for patients with no other options

NCT ID NCT00420563

Completed Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two treatments for people with advanced cancer who cannot have standard therapy. One group took a low-dose chemotherapy pill (cyclophosphamide) daily, and the other took a hormone pill (megestrol). The goal was to see which treatment could slow cancer growth for at least two months. The trial enrolled 88 adults with various cancers (except breast cancer) and measured how long the cancer stayed under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cyclophosphamide (low-dose chemotherapy) and megestrol (hormone therapy)
What this could lead to: If successful, this could offer a gentle, long-term chemotherapy option for patients with advanced cancer who have run out of standard treatments.
What could go wrong: This is a small, early-phase trial with only 88 participants. The benefit may be modest, and side effects like low blood counts or blood clots are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

Centre Hospitalier Regional - Dermatology

Lille, 59035, France
Centre Hospitalier Regional - Oncology

Lille, 59035, France
Centre Oscar Lambret

Lille, 59020, France
Hopital Saint Vincent

Lille, 59020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.